Covid-19: Bulgaria extends state of epidemic emergency until March 31, 2022

Covid-19: Bulgaria extends state of epidemic emergency until March 31, 2022
Image: BGNES/archive

The caretaker government on November 24 adopted a decision to extend the state of epidemic emergency in Bulgaria until March 31, 2022.

The cabinet also approved the allocation of funds for the purchase of new drugs to treat COVID-19.

The spread of COVID-19 in the country marks the intensive development of another pandemic wave. All districts of the country are affected, and in 93% of them the 14-day morbidity is more than 500 cases per 100,000 population (in 8 of which it exceeds 1,000 new cases per 100,000 population).

The vaccination coverage in the country is 25.53% and is far from the EU's target of fully vaccinating 70% of the adults and the population as a whole, according to the government's press office.

This contributes to the reported high incidence rates among unvaccinated individuals, who account for over 85% of all SARS-CoV-2 infected individuals.

The extension of the epidemic emergency period aims to limit the spread of COVID-19.

At today's meeting, the caretaker cabinet changed the approved maximum amounts of expenditures in the budget of the Ministry of Health for 2021.

In this way, the ministry will be able to conclude contracts for the provision of three medicinal products for the treatment of COVlD-19, the press office of the Council of Ministers points out.

Molnupiravir is an antiviral medicine for non-hospitalised adult patients with mild to moderate COVID-19 and at least one risk factor associated with progression to severe COVID-19. The medicine is for oral therapy for outpatient use and will be available in a pack for a five-day course of treatment.

Regkirona monoclonal antibody is for the treatment of moderate COVID-19, with a prognosis for severe disease and/or hospitalisation. Clinical data demonstrate a proven threefold reduction in hospitalisations after drug administration.

Anakinra is suitable for patients with COVID-19-induced pneumonia who are at risk of progression to severe respiratory failure. It is given by injection under the skin.

Кампании Виж повече